Cellebrite DI Ltd (CLBT) concluded trading on Wednesday at a closing price of $12.79, with 2.98 million shares of worth about $38.16 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 59.08% during that period and on July 17, 2024 the price saw a gain of about 6.05%. Currently the company’s common shares owned by public are about 203.23M shares, out of which, 61.29M shares are available for trading.
Stock saw a price change of 10.16% in past 5 days and over the past one month there was a price change of 5.62%. Year-to-date (YTD), CLBT shares are showing a performance of 47.69% which increased to 78.13% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.36 but also hit the highest price of $12.67 during that period. The average intraday trading volume for Cellebrite DI Ltd shares is 1.06 million. The stock is currently trading 7.25% above its 20-day simple moving average (SMA20), while that difference is up 10.96% for SMA50 and it goes to 30.34% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cellebrite DI Ltd (NASDAQ: CLBT) currently have 203.23M outstanding shares and institutions hold larger chunk of about 30.60% of that.
The stock has a current market capitalization of $2.63B and its 3Y-monthly beta is at 1.48. It has posted earnings per share of -$0.58 in the same period. It has Quick Ratio of 1.55. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CLBT, volatility over the week remained 3.22% while standing at 2.76% over the month.
Stock’s fiscal year EPS is expected to rise by 52.09% while it is estimated to increase by 220.03% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Needham on March 28, 2024 offering a Buy rating for the stock and assigned a target price range of between $13 and $13.50 to it. On February 16, 2024, BofA Securities Upgrade their recommendations, while on July 19, 2023, Craig Hallum Initiated their ratings for the stock with a price target of $11. Stock get a Mkt perform rating from William Blair on August 12, 2022.
